[go: up one dir, main page]

PE20160052A1 - Composicion farmaceutica de clorhidrato de s-cetamina - Google Patents

Composicion farmaceutica de clorhidrato de s-cetamina

Info

Publication number
PE20160052A1
PE20160052A1 PE2015001997A PE2015001997A PE20160052A1 PE 20160052 A1 PE20160052 A1 PE 20160052A1 PE 2015001997 A PE2015001997 A PE 2015001997A PE 2015001997 A PE2015001997 A PE 2015001997A PE 20160052 A1 PE20160052 A1 PE 20160052A1
Authority
PE
Peru
Prior art keywords
hydrochloride
cetamine
pharmaceutical composition
formulation
depression
Prior art date
Application number
PE2015001997A
Other languages
English (en)
Inventor
Esther D G Basstanie
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeijer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20160052A1 publication Critical patent/PE20160052A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion esta dirigida a una formulacion acuosa de clorhidrato de S-cetamina, preferentemente para la administracion nasal, en donde la formulacion no contiene un conservante antimicrobiano, ademas es util en el tratamiento de la depresion
PE2015001997A 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-cetamina PE20160052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791505P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20160052A1 true PE20160052A1 (es) 2016-01-28

Family

ID=50549465

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002294A PE20191796A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina
PE2015001997A PE20160052A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-cetamina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019002294A PE20191796A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina

Country Status (26)

Country Link
US (2) US20140275277A1 (es)
EP (3) EP3498268A1 (es)
KR (3) KR20230156807A (es)
CN (3) CN116251084A (es)
AU (6) AU2014228324B2 (es)
CL (1) CL2015002733A1 (es)
CR (1) CR20150480A (es)
CY (1) CY1121928T1 (es)
DK (1) DK2968221T3 (es)
ES (1) ES2745024T3 (es)
HR (1) HRP20191477T1 (es)
HU (1) HUE045982T2 (es)
LT (1) LT2968221T (es)
ME (1) ME03465B (es)
MX (2) MX373678B (es)
MY (2) MY203693A (es)
NZ (1) NZ712270A (es)
PE (2) PE20191796A1 (es)
PH (2) PH12021552333A1 (es)
PL (1) PL2968221T3 (es)
PT (1) PT2968221T (es)
RS (1) RS59130B1 (es)
SG (3) SG10201912735TA (es)
SI (1) SI2968221T1 (es)
SM (1) SMT201900472T1 (es)
WO (1) WO2014143646A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
EP3094312B1 (en) * 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
MX2019012285A (es) * 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
PL3628313T3 (pl) 2018-09-28 2025-06-23 Novohale Therapeutics, Llc Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020239243A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
EP3976145B1 (en) 2019-05-31 2025-01-15 Celon Pharma S.A. An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
US20220339123A1 (en) * 2019-09-13 2022-10-27 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
TW202135787A (zh) * 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
EP4076410B1 (en) * 2019-12-20 2025-09-10 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
CN114903840A (zh) * 2021-02-08 2022-08-16 四川普锐特药业有限公司 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
CN116942647A (zh) * 2022-04-26 2023-10-27 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途
US20250248951A1 (en) 2022-04-26 2025-08-07 Yichang Humanwell Pharmaceutical Co., Ltd. Esketamine liquid preparation and use thereof
EP4629989A2 (en) * 2022-12-07 2025-10-15 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN104902883A (zh) * 2012-08-23 2015-09-09 斯图亚特·L·韦格 抗焦虑组合物、制剂及使用方法

Also Published As

Publication number Publication date
RS59130B1 (sr) 2019-09-30
KR20210028278A (ko) 2021-03-11
SG10201802106TA (en) 2018-04-27
AU2019200696B2 (en) 2020-10-08
PT2968221T (pt) 2019-09-13
MX2015012342A (es) 2016-06-06
US20140275277A1 (en) 2014-09-18
HRP20191477T1 (hr) 2019-12-13
PE20191796A1 (es) 2019-12-24
MY191332A (en) 2022-06-16
SMT201900472T1 (it) 2019-09-09
SG11201507358VA (en) 2015-10-29
HUE045982T2 (hu) 2020-01-28
CY1121928T1 (el) 2020-10-14
ES2745024T3 (es) 2020-02-27
BR112015022970A2 (pt) 2017-07-18
AU2019200705B2 (en) 2020-10-08
AU2023200976A1 (en) 2023-03-23
AU2019200702B2 (en) 2020-10-08
BR112015022970A8 (pt) 2019-11-26
ME03465B (me) 2020-01-20
PL2968221T3 (pl) 2020-01-31
SG10201912735TA (en) 2020-02-27
SI2968221T1 (sl) 2019-08-30
MX373678B (es) 2020-06-26
WO2014143646A1 (en) 2014-09-18
AU2019200696A1 (en) 2019-02-21
AU2014228324B2 (en) 2019-01-31
EP2968221B1 (en) 2019-06-19
PH12021552333A1 (en) 2022-08-01
EP4309735A2 (en) 2024-01-24
KR20150129023A (ko) 2015-11-18
CR20150480A (es) 2015-10-26
LT2968221T (lt) 2019-07-25
EP2968221A1 (en) 2016-01-20
CN105073103A (zh) 2015-11-18
EP4309735A3 (en) 2024-04-17
NZ712270A (en) 2020-02-28
AU2021200072A1 (en) 2021-03-18
AU2019200705A1 (en) 2019-02-21
CN116251084A (zh) 2023-06-13
AU2019200702A1 (en) 2019-02-21
CL2015002733A1 (es) 2016-03-04
KR20230156807A (ko) 2023-11-14
CN111297803A (zh) 2020-06-19
AU2014228324A1 (en) 2015-09-17
PH12015501957A1 (en) 2016-01-11
US20140275276A1 (en) 2014-09-18
EP3498268A1 (en) 2019-06-19
DK2968221T3 (da) 2019-08-05
MX386479B (es) 2025-03-18
AU2023200976B2 (en) 2025-03-27
MY203693A (en) 2024-07-14

Similar Documents

Publication Publication Date Title
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MX375254B (es) Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CO2017007316A2 (es) Formulación farmacéutica
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX381932B (es) Composicion intranasal que comprende betahistina.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX393608B (es) Profilactico o agente terapeutico para queratitis fungica.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201890597A1 (ru) Содержащая цинеол водная композиция для назального применения
BR112016016674A2 (pt) Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla
UA90602U (uk) Фармацевтична композиція комбінованої дії

Legal Events

Date Code Title Description
FG Grant, registration